We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

PPIs and Fat Absorption in CF and EPI

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03551691
Recruitment Status : Active, not recruiting
First Posted : June 11, 2018
Last Update Posted : April 12, 2022
Chiesi USA, Inc.
Information provided by (Responsible Party):
Children's Hospital of Philadelphia

Brief Summary:
This is a clinical trial with a cross over design investigating the effect of the proton pump inhibitor omeprazole on fat malabsorption in subjects with cystic fibrosis and pancreatic insufficiency. Participants will be randomized to receive either omeprazole or placebo for 28 days, then cross over and receive omeprazole or placebo for another 28 days. Markers of fat absorption will be measured after each treatment course.

Condition or disease Intervention/treatment Phase
Pancreatic Insufficiency Cystic Fibrosis Drug: Omeprazole 40mg Capsule Drug: Placebo oral capsule Phase 2

Detailed Description:

Fat malabsorption contributes to poor nutritional status in people with cystic fibrosis (CF) and exocrine pancreatic insufficiency (EPI). Prescribing gastric acid-reducing agents such as proton pump inhibitors (PPIs) and histamine receptor antagonists (H2RAs) as an adjunct to pancreatic enzyme replacement therapy (PERT) to improve PERT efficacy and dietary fat absorption has become accepted clinical practice in CF, despite limited evidence to support the practice. Establishing the efficacy and true health benefit of acid suppression for nutritional status and outcomes in CF is particularly important in light of potential health risks and cost associated with long-term or even lifetime use of these medications.

This study aims to characterize changes in fat malabsorption using the coefficient of fat absorption (CFA) as the primary endpoint in subjects who are on and off acid suppression with a PPI in addition to PERT. Additionally, the SmartPill® will be used to evaluate duodenal power of hydrogen (pH) while on and off acid suppression, and the malabsorption blood test (MBT) will be used to characterize changes in fat absorption. Associations will be explored between changes in nutritional status (weight, height, BMI), clinical GI symptoms, and quality of life in subjects treated with PPI vs. placebo.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 16 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Proton Pump Inhibitors and Fat Absorption in Subjects With Cystic Fibrosis and Pancreatic Insufficiency
Actual Study Start Date : August 7, 2018
Actual Primary Completion Date : December 31, 2021
Estimated Study Completion Date : June 30, 2022

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Cystic Fibrosis

Arm Intervention/treatment
Active Comparator: Treatment Arm
Subjects will take omeprazole 40mg daily for 28 days, then undergo assessments of fat absorption.
Drug: Omeprazole 40mg Capsule
Omeprazole 40mg daily for 28 days

Placebo Comparator: Placebo Arm
Subjects will take a placebo daily for 28 days, then undergo assessments of fat absorption.
Drug: Placebo oral capsule
Identically-appearing capsule to omeprazole

Primary Outcome Measures :
  1. Coefficient of fat absorption [ Time Frame: After 28 days of treatment or placebo ]
    Gold standard measurement of fat malabsorption

Secondary Outcome Measures :
  1. Duodenal pH [ Time Frame: After 28 days of treatment or placebo ]
    Change in duodenal pH as measured by the SmartPill

  2. Fat absorption via Malabsorption Blood Test [ Time Frame: After 28 days of treatment or placebo ]
    Measurement of serum pentadecanoic acid and heptadecanoic acid

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   12 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Cystic fibrosis and pancreatic insufficiency (Fecal elastase <200 ug/g stool)
  • Age ≥12 years
  • In usual state of good health
  • Willing to participate in a four-month study with three visits

Exclusion Criteria:

  • Forced expiratory vital capacity at one second (FEV1) <40% predicted
  • Pregnancy or breast feeding
  • Other illness affecting growth or nutritional status
  • Unwillingness to continue their clinically established PERT dose for the duration of the study
  • Use of other medication that affects dietary fat absorption
  • Allergy to soy products
  • Allergy to safflower products
  • For subjects ≥18 years, celiac disease or allergy to gluten

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03551691

Layout table for location information
United States, Pennsylvania
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, United States, 19146
Sponsors and Collaborators
Children's Hospital of Philadelphia
Chiesi USA, Inc.
Layout table for investigator information
Principal Investigator: Virginia A Stallings, MD Children's Hospital of Philadelphia

Layout table for additonal information
Responsible Party: Children's Hospital of Philadelphia
ClinicalTrials.gov Identifier: NCT03551691    
Other Study ID Numbers: 17-014666
First Posted: June 11, 2018    Key Record Dates
Last Update Posted: April 12, 2022
Last Verified: April 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Individual participant data that underlie the results reported will be shared upon request, after deidentification.
Supporting Materials: Study Protocol
Informed Consent Form (ICF)
Time Frame: The data will be available immediately upon publication.
Access Criteria: Contact brownellj@email.chop.edu. Requestors will need to sign a data access agreement.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Keywords provided by Children's Hospital of Philadelphia:
fat absorption
pancreatic enzyme
Additional relevant MeSH terms:
Layout table for MeSH terms
Cystic Fibrosis
Exocrine Pancreatic Insufficiency
Pathologic Processes
Pancreatic Diseases
Digestive System Diseases
Lung Diseases
Respiratory Tract Diseases
Genetic Diseases, Inborn
Infant, Newborn, Diseases
Anti-Ulcer Agents
Gastrointestinal Agents
Proton Pump Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action